Item 7.01 Regulation FD Disclosure.

On April 26, 2022, Avadel Pharmaceuticals plc issued a press release titled "Avadel Pharmaceuticals Provides Comment on Recent Trading Activity." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.





Item 9.01. Exhibits




(d) Exhibits



  99.1         Press release issued by the Company on April 26, 2022, furnished
             herewith.

104          Cover Page Interactive Data File (embedded with the Inline XBRL
             document).

© Edgar Online, source Glimpses